Bone Cancer News
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”